Results 131 to 140 of about 12,438,664 (296)
Molecular Oncology, EarlyView.Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Molecular Oncology, Volume 20, Issue 6, Page 1612-1625, June 2026.Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
Takayasu's arteritis in Turkey - clinical and angiographic features of 248 patients
, 2009 Objective. Takayasu's arteritis (TA) is a chronic, inflammatory vasculitis affecting the aorta and its major branches. Although it is more, prevalent in Far-East Asia, the distribution of the disease is worldwide with different vascular involvement ...
core
Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment
Molecular Oncology, EarlyView.This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley +1 more source
Clinical Trials Unit Newsletter - Issue 02 [PDF]
What\u27s inside this issue: The Clinical Trials Summit of Pakistan 2025 Biosimilar trials at CTU! Completion of the Panbio Self-Test Enrolment Coming Together for Better Cancer Care Informative Snippets Clinical Trials Unit celebrates Clinical Trials ...
Clinical Trials Unit (CTU),
core
Molecular Oncology, EarlyView.In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge +17 more
wiley +1 more source
Clinical Laboratory Improvement Advisory Committee (CLIAC) recommendations table [PDF]
Table of recommendations from the CDC's Clinical Laboratory Improvement Advisory Committee made October 28-29, 1992-November 2-3, 2016.Updated 02/06 ...
core
Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers
Molecular Oncology, EarlyView.This study employed machine learning methodologies to perform the subtype‐specific classification of RNA‐seq data sets, which are mapped on enhancers from TCGA‐derived breast cancer patients. Their integration with gene expression (referred to as ProxCReAM eRNAs) and chromatin accessibility profiles has the potential to identify lineage‐specific and ...
Aamena Y. Patel +6 more
wiley +1 more source
Cutis laxa autosómica recesiva Descripción fenotípica de un caso y revisión de la literatura
Avances en Biomedicina, 2016 Cutis laxa is a rare skin disorder, characterized by redundant, inelastic and with an appearance of premature aging. It can be associated with the alteration of other organs involved in their prognosis.
María Angelina Lacruz de Ortega +5 more
doaj